BeOne Medicines wins U.S. FDA approval for TEVIMBRA-based regimen
BeOne Medicines announces U.S. FDA approval for a TEVIMBRA-based regimen for first-line HER2+ GEA.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.